Redox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology

Abstract: Considerable evidence is mounting that dyshomeostasis of the redox‐active biometals, Cu and Fe, and oxidative stress contribute to the neuropathology of Alzheimer's disease (AD). Present data suggest that metals can interact directly with Aβ peptide, the principal component of β‐amyloid that is one of the primary lesions in AD. The binding of metals to Aβ modulates several physiochemical properties of Aβ that are thought to be central to the pathogenicity of the peptide. First, we and others have shown that metals can promote the in vitro aggregation into tinctorial Aβ amyloid. Studies have confirmed that insoluble amyloid plaques in postmortem AD brain are abnormally enriched in Cu, Fe, and Zn. Conversely, metal chelators dissolve these proteinaceous deposits from postmortem AD brain tissue and attenuate cerebral Aβ amyloid burden in APP transgenic mouse models of AD. Second, we have demonstrated that redox‐active Cu(II) and, to a lesser extent, Fe(III) are reduced in the presence of Aβ with concomitant production of reactive oxygen species (ROS), hydrogen peroxide (H2O2) and hydroxyl radical (OH•). These Aβ/metal redox reactions, which are silenced by redox‐inert Zn(II), but exacerbated by biological reducing agents, may lead directly to the widespread oxidation damages observed in AD brains. Moreover, studies have also shown that H2O2 mediates Aβ cellular toxicity and increases the production of both Aβ and amyloid precursor protein (APP). Third, the 5′ untranslated region (5′UTR) of APP mRNA has a functional iron‐response element (IRE), which is consistent with biochemical evidence that APP is a redox‐active metalloprotein. Hence, the redox interactions between Aβ, APP, and metals may be at the heart of a pathological positive feedback system wherein Aβ amyloidosis and oxidative stress promote each other. The emergence of redox‐active metals as key players in AD pathogenesis strongly argues that amyloid‐specific metal‐complexing agents and antioxidants be investigated as possible disease‐modifying agents for treating this horrible disease.

[1]  W. Markesbery,et al.  Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  W. D. Ehmann,et al.  Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease , 1995, Neurology.

[3]  A. Barnea,et al.  Brain tissue accumulates 67copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity, high capacity process. , 1988, The Journal of biological chemistry.

[4]  C. Masters,et al.  Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. , 1999, The Journal of biological chemistry.

[5]  G. Perry,et al.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Patrizia Mecocci,et al.  Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease , 1994, Annals of neurology.

[7]  M. Mattson,et al.  β-Amyloid Peptide Free Radical Fragments Initiate Synaptosomal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer′s Disease , 1994 .

[8]  D. Borchelt,et al.  Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins , 1995, Neuron.

[9]  S. Asano,et al.  Inhibition of Amyloid Protein Aggregation and Neurotoxicity by Rifampicin , 1996, The Journal of Biological Chemistry.

[10]  D. Butterfield,et al.  Vitamin E Prevents Alzheimer's Amyloid beta-Peptide (1-42)-Induced Neuronal Protein Oxidation and Reactive Oxygen Species Production. , 2000, Journal of Alzheimer's disease : JAD.

[11]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[12]  M. Vitek,et al.  Amyloid β Peptides Do Not Form Peptide-derived Free Radicals Spontaneously, but Can Enhance Metal-catalyzed Oxidation of Hydroxylamines to Nitroxides* , 1999, The Journal of Biological Chemistry.

[13]  N. Robakis,et al.  Immunohistochemical evidence of antioxidant stress in Alzheimer's disease , 1992 .

[14]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[15]  Khadija Iqbal,et al.  Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia , 2004, Acta Neuropathologica.

[16]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[17]  A. Mackinnon,et al.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.

[18]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[19]  J. Cummings,et al.  Alzheimer's disease , 1998, Neurology.

[20]  Xudong Huang,et al.  Evidence that the β-Amyloid Plaques of Alzheimer's Disease Represent the Redox-silencing and Entombment of Aβ by Zinc* , 2000, The Journal of Biological Chemistry.

[21]  S. V. van Duinen,et al.  Different processing of Alzheimer's beta-protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. , 1988, Biochemical and biophysical research communications.

[22]  B. Ghetti,et al.  A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. , 1991, Science.

[23]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[24]  W R Markesbery,et al.  Oxidative stress hypothesis in Alzheimer's disease. , 1997, Free radical biology & medicine.

[25]  Xudong Huang,et al.  The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.

[26]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[27]  T. Tabira,et al.  High expression on Kunitz-type protease inhibitor-containing substances in the cerebral vessels of patients with Down syndrome. , 1994, The Tohoku journal of experimental medicine.

[28]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[30]  Association of interleukin‐1 gene polymorphisms with Alzheimer's disease , 2000, Annals of neurology.

[31]  M. Mullan,et al.  β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.

[32]  M. Baudry,et al.  beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[34]  A. Bruce β-Amyloid toxicity in organotypic cultures : protection by EUK-8, a synthetic catalytic free radical scavenger , 1996 .

[35]  C. Goetz,et al.  Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients , 1996, Neurology.

[36]  R. Dodel,et al.  α2‐Macroglobulin as a β‐Amyloid Peptide‐Binding Plasma Protein , 1997 .

[37]  P. S. St George-Hyslop,et al.  Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. , 1987, Science.

[38]  J. Hardy,et al.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene , 1991, Nature.

[39]  R. Tanzi,et al.  Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. , 1999, Metal ions in biological systems.

[40]  Mark A. Smith,et al.  4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease , 1997, Journal of neurochemistry.

[41]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[42]  N. Greig,et al.  Alzheimer’s disease drug discovery targeted to the APP mRNA 5′Untranslated region , 2002, Journal of Molecular Neuroscience.

[43]  Xudong Huang,et al.  Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). , 2002, The Journal of biological chemistry.

[44]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[45]  C. Vigo‐Pelfrey,et al.  Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid , 1993 .

[46]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[47]  Xudong Huang,et al.  An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.

[48]  D. Butterfield,et al.  Direct evidence of oxidative injury produced by the Alzheimer's β-Amyloid peptide (1–40) in cultured hippocampal neurons , 1995, Experimental Neurology.

[49]  D. Mann,et al.  Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome , 1996, Nature Medicine.

[50]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[51]  D. Selkoe,et al.  Enhanced Production and Oligomerization of the 42-residue Amyloid β-Protein by Chinese Hamster Ovary Cells Stably Expressing Mutant Presenilins* , 1997, The Journal of Biological Chemistry.

[52]  J. Connor,et al.  A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.

[53]  Xudong Huang,et al.  Zinc-induced Alzheimer’s Aβ1–40 Aggregation Is Mediated by Conformational Factors* , 1997, The Journal of Biological Chemistry.

[54]  J. Reed,et al.  Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease , 1991 .

[55]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[56]  S. Estus,et al.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing. , 1992, Science.

[57]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[58]  J. Connor,et al.  Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. , 2000, Cellular and molecular biology.

[59]  C. Behl,et al.  Hydrogen peroxide mediates amyloid β protein toxicity , 1994, Cell.

[60]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Steven M. Horvath,et al.  Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.

[62]  C. Berr,et al.  Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type--place of the extracellular glutathione peroxidase. , 1996, Free radical biology & medicine.

[63]  D. Price,et al.  Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. , 1995, The American journal of pathology.

[64]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.

[65]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[66]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[67]  R. Tanzi,et al.  Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. , 1999, Biochemistry.

[68]  C. Masters,et al.  The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I) , 1996, Science.

[69]  C. Masters,et al.  Rapid induction of Alzheimer A beta amyloid formation by zinc. , 1994, Science.

[70]  E. Huehns,et al.  11 The toxic effects of desferrioxamine , 1989 .

[71]  B. Hyman,et al.  Multiple, diverse senile plaque–associated proteins are ligands of an apolipoprotein e receptor, the α2‐macroglobulin receptor/low‐density‐lipoprotein receptor—related protein , 1995, Annals of neurology.

[72]  S. Younkin,et al.  Amyloid β protein levels in cerebrospinal fluid are elevated in early‐onset Alzheimer's disease , 1994 .

[73]  B. Halliwell,et al.  Oxygen toxicity, oxygen radicals, transition metals and disease. , 1984, The Biochemical journal.

[74]  C. Masters,et al.  Homocysteine potentiates copper‐ and amyloid beta peptide‐mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's‐type neurodegenerative pathways , 2001, Journal of neurochemistry.

[75]  B. Winblad,et al.  Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. , 1991, Journal of neural transmission. Parkinson's disease and dementia section.

[76]  J. Connor,et al.  Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease , 1993, Neuroscience Letters.

[77]  Xudong Huang,et al.  Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis* , 1998, The Journal of Biological Chemistry.

[78]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[79]  G. Perry,et al.  Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. , 1994, The American journal of pathology.

[80]  G. Mashour,et al.  Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. , 1994, Alzheimer disease and associated disorders.

[81]  Lars Bertram,et al.  New Frontiers in Alzheimer's Disease Genetics , 2001, Neuron.

[82]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[83]  M. Tabaton,et al.  Amyloid‐β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress , 1998, Journal of neurochemistry.

[84]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.

[85]  Carl W. Cotman,et al.  In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.

[86]  D. Butterfield,et al.  Brain Regional Correspondence Between Alzheimer's Disease Histopathology and Biomarkers of Protein Oxidation , 1995, Journal of neurochemistry.

[87]  K. Blennow,et al.  Treatment of Alzheimer’s Disease with Clioquinol , 2001, Dementia and Geriatric Cognitive Disorders.

[88]  N. Robakis,et al.  CHROMOSOME 21q21 SUBLOCALISATION OF GENE ENCODING BETA-AMYLOID PEPTIDE IN CEREBRAL VESSELS AND NEURITIC (SENILE) PLAQUES OF PEOPLE WITH ALZHEIMER DISEASE AND DOWN SYNDROME , 1987, The Lancet.

[89]  M G McInnis,et al.  Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. , 2000, Science.

[90]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[91]  Xudong Huang,et al.  Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. , 2008, Journal of neurochemistry.

[92]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[93]  L. Villa-komaroff,et al.  Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease , 1988, Nature.

[94]  C. Masters,et al.  Aqueous Dissolution of Alzheimer’s Disease Aβ Amyloid Deposits by Biometal Depletion* , 1999, The Journal of Biological Chemistry.